These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25534390)

  • 61. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
    Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
    Warner E; Hill K; Causer P; Plewes D; Jong R; Yaffe M; Foulkes WD; Ghadirian P; Lynch H; Couch F; Wong J; Wright F; Sun P; Narod SA
    J Clin Oncol; 2011 May; 29(13):1664-9. PubMed ID: 21444874
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Update on screening breast MRI in high-risk women.
    Boetes C
    Obstet Gynecol Clin North Am; 2011 Mar; 38(1):149-58, viii-ix. PubMed ID: 21419331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
    Shah P; Rosen M; Stopfer J; Siegfried J; Kaltman R; Mason B; Armstrong K; Nathanson KL; Schnall M; Domchek SM
    Breast Cancer Res Treat; 2009 Dec; 118(3):539-46. PubMed ID: 19609668
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Self-reported mammography use following BRCA1/2 genetic testing may be overestimated.
    Larouche G; Bouchard K; Chiquette J; Desbiens C; Simard J; Dorval M
    Fam Cancer; 2012 Mar; 11(1):27-32. PubMed ID: 22080962
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer.
    Kam JK; Naidu P; Rose AK; Mann GB
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):400-6. PubMed ID: 23870334
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
    Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
    Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Online tool to guide decisions for BRCA1/2 mutation carriers.
    Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
    J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
    Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
    Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
    Warner E; Plewes DB; Shumak RS; Catzavelos GC; Di Prospero LS; Yaffe MJ; Goel V; Ramsay E; Chart PL; Cole DE; Taylor GA; Cutrara M; Samuels TH; Murphy JP; Murphy JM; Narod SA
    J Clin Oncol; 2001 Aug; 19(15):3524-31. PubMed ID: 11481359
    [TBL] [Abstract][Full Text] [Related]  

  • 72. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
    Kriege M; Brekelmans CT; Obdeijn IM; Boetes C; Zonderland HM; Muller SH; Kok T; Manoliu RA; Besnard AP; Tilanus-Linthorst MM; Seynaeve C; Bartels CC; Kaas R; Meijer S; Oosterwijk JC; Hoogerbrugge N; Tollenaar RA; Rutgers EJ; de Koning HJ; Klijn JG
    Breast Cancer Res Treat; 2006 Nov; 100(1):109-19. PubMed ID: 16791481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
    Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The frequency of missed breast cancers in women participating in a high-risk MRI screening program.
    Vreemann S; Gubern-Merida A; Lardenoije S; Bult P; Karssemeijer N; Pinker K; Mann RM
    Breast Cancer Res Treat; 2018 Jun; 169(2):323-331. PubMed ID: 29383629
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
    Kurian AW; Sigal BM; Plevritis SK
    J Clin Oncol; 2010 Jan; 28(2):222-31. PubMed ID: 19996031
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI.
    Feig S
    Obstet Gynecol Clin North Am; 2011 Mar; 38(1):179-96, ix. PubMed ID: 21419333
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
    Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
    Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
    Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
    Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.